8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      “After viral load testing, I get my results so I get to know which path my life is taking me”: qualitative insights on routine centralized and point-of-care viral load testing in western Kenya from the Opt4Kids and Opt4Mamas studies

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Viral suppression (VS) is a marker of effective HIV therapy, and viral load (VL) testing is critical for treatment monitoring, especially in high-risk groups such as children and pregnant/postpartum women. Although routine VL testing, via centralized laboratory networks, was implemented in Kenya starting in 2014, optimization and sustainable scale up of VL testing are still needed.

          Methods

          We conducted a mixed methods study to evaluate the impact of higher frequency, point-of-care (POC) VL testing in optimizing VS among children and pregnant/postpartum women on antiretroviral treatment (ART) in five HIV treatment facilities in western Kenya in the Opt4Kids and Opt4Mamas studies. We conducted 68 key informant interviews (KIIs) from December 2019 to December 2020 with children and pregnant women living with HIV, child caregivers, providers, laboratory/facility leadership, and county- or national-level policymakers. Our KII guide covered the following domains: (1) barriers and facilitators to ART use and VS, (2) literacy and experiences with VL in routine care and via study, and (3) opinions on how to scale up VL testing for optimal programmatic use. We used inductive coding and thematic analysis to identify dominant themes with convergent and divergent subthemes.

          Results

          Three main themes regarding VL testing emerged from our analysis. (1) Key informants uniformly contrasted POC VL testing’s faster results turnaround, higher accessibility, and likely cost-effectiveness against centralized VL testing. (2) Key informants also identified areas of improvement for POC VL testing in Kenya, such as quality control, human resource and infrastructure capacity, supply chain management, and integration of VL testing systems. (3) To enable successful scale-up of VL testing, key informants proposed expanding the POC VL testing scheme, electronic medical records systems, conducting quality checks locally, capacity building and developing strong partnerships between key stakeholders.

          Conclusion

          The more accessible, decentralized model of POC VL testing was deemed capable of overcoming critical challenges associated with centralized VL testing and was considered highly desirable for optimizing VS for children and pregnant/postpartum women living with HIV. While POC VL testing has the potential to improve VS rates among these populations, additional research is needed to develop strategies for ensuring the sustainability of POC VL testing programs.

          Trial registration

          NCT03820323, 29/01/2019

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s12913-022-08593-z.

          Related collections

          Most cited references31

          • Record: found
          • Abstract: not found
          • Article: not found

          Using thematic analysis in psychology

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Prevention of HIV-1 infection with early antiretroviral therapy.

            Antiretroviral therapy that reduces viral replication could limit the transmission of human immunodeficiency virus type 1 (HIV-1) in serodiscordant couples. In nine countries, we enrolled 1763 couples in which one partner was HIV-1-positive and the other was HIV-1-negative; 54% of the subjects were from Africa, and 50% of infected partners were men. HIV-1-infected subjects with CD4 counts between 350 and 550 cells per cubic millimeter were randomly assigned in a 1:1 ratio to receive antiretroviral therapy either immediately (early therapy) or after a decline in the CD4 count or the onset of HIV-1-related symptoms (delayed therapy). The primary prevention end point was linked HIV-1 transmission in HIV-1-negative partners. The primary clinical end point was the earliest occurrence of pulmonary tuberculosis, severe bacterial infection, a World Health Organization stage 4 event, or death. As of February 21, 2011, a total of 39 HIV-1 transmissions were observed (incidence rate, 1.2 per 100 person-years; 95% confidence interval [CI], 0.9 to 1.7); of these, 28 were virologically linked to the infected partner (incidence rate, 0.9 per 100 person-years, 95% CI, 0.6 to 1.3). Of the 28 linked transmissions, only 1 occurred in the early-therapy group (hazard ratio, 0.04; 95% CI, 0.01 to 0.27; P<0.001). Subjects receiving early therapy had fewer treatment end points (hazard ratio, 0.59; 95% CI, 0.40 to 0.88; P=0.01). The early initiation of antiretroviral therapy reduced rates of sexual transmission of HIV-1 and clinical events, indicating both personal and public health benefits from such therapy. (Funded by the National Institute of Allergy and Infectious Diseases and others; HPTN 052 ClinicalTrials.gov number, NCT00074581.).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Scale-up of Routine Viral Load Testing in Resource-Poor Settings: Current and Future Implementation Challenges

              Cost and complexity have hindered implementation to date of viral load testing in resource-limited settings. If rapid and timely scale-up is to become a reality, numerous factors will need to be addressed, including health and laboratory system strengthening, pricing, and multiple programmatic and funding challenges.
                Bookmark

                Author and article information

                Contributors
                rcpatel@uw.edu
                Journal
                BMC Health Serv Res
                BMC Health Serv Res
                BMC Health Services Research
                BioMed Central (London )
                1472-6963
                17 December 2022
                17 December 2022
                2022
                : 22
                : 1540
                Affiliations
                [1 ]GRID grid.34477.33, ISNI 0000000122986657, School of Public Health, , University of Washington, ; Seattle, WA USA
                [2 ]GRID grid.34477.33, ISNI 0000000122986657, Department of Medicine, , University of Washington, ; Seattle, WA USA
                [3 ]GRID grid.34477.33, ISNI 0000000122986657, Jackson School of International Studies, , University of Washington, ; Seattle, WA USA
                [4 ]Health Innovations Kenya (HIK), Kisumu, Kenya
                [5 ]University of Washington-Kenya, Nairobi, Kenya
                [6 ]Department of Health, Siaya, Kenya
                [7 ]Drugs for Neglected Diseases Initiative, Nairobi, Kenya
                [8 ]Department of Health, Kisumu, Kenya
                [9 ]GRID grid.33058.3d, ISNI 0000 0001 0155 5938, Family AIDS Care and Education Services, , Kenya Medical Research Institute, ; Kisumu, Kenya
                [10 ]GRID grid.33058.3d, ISNI 0000 0001 0155 5938, Kenya Medical Research Institute-CDC, ; Kisian, Kenya
                [11 ]GRID grid.415727.2, National HIV Reference Laboratory, , Kenya Ministry of Health, ; Nairobi, Kenya
                [12 ]GRID grid.34477.33, ISNI 0000000122986657, Department of Global Health, , University of Washington, ; Seattle, WA USA
                [13 ]GRID grid.34477.33, ISNI 0000000122986657, Department of Pediatrics, , University of Washington, ; Seattle, WA USA
                [14 ]GRID grid.34477.33, ISNI 0000000122986657, Department of Epidemiology, , University of Washington, ; Seattle, WA USA
                [15 ]GRID grid.241116.1, ISNI 0000000107903411, Department of Pediatrics, , University of Colorado, ; Denver, CO USA
                Article
                8593
                10.1186/s12913-022-08593-z
                9758673
                36528677
                6cb9e03d-327a-455a-91f6-5de7fdfb49d8
                © The Author(s) 2022

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 18 June 2022
                : 21 September 2022
                Funding
                Funded by: US National Institutes of Mental Health
                Award ID: NIH R34MH115769
                Award ID: NIH R34MH115769
                Award ID: NIH R34MH115769
                Award ID: NIH R34MH115769
                Award ID: NIH R34MH115769
                Award ID: NIH R34MH115769
                Award ID: NIH R34MH115769
                Award ID: NIH R34MH115769
                Award ID: NIH R34MH115769
                Award ID: NIH R34MH115769
                Award ID: NIH R34MH115769
                Award ID: NIH R34MH115769
                Award ID: NIH R34MH115769
                Award ID: NIH R34MH115769
                Award ID: NIH R34MH115769
                Award ID: NIH R34MH115769
                Award ID: NIH R34MH115769
                Award ID: NIH R34MH115769
                Award ID: NIH R34MH115769
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100005627, Thrasher Research Fund;
                Award ID: 15240
                Award ID: 15240
                Award ID: 15240
                Award ID: 15240
                Award ID: 15240
                Award ID: 15240
                Award ID: 15240
                Award ID: 15240
                Award ID: 15240
                Award ID: 15240
                Award ID: 15240
                Award ID: 15240
                Award ID: 15240
                Award ID: 15240
                Award ID: 15240
                Award ID: 15240
                Award ID: 15240
                Award ID: 15240
                Award ID: 15240
                Award Recipient :
                Funded by: National Institutes of Allergy and Infectious Diseases
                Award ID: NIH R21AI145450
                Award ID: NIH R21AI145450
                Award ID: NIH R21AI145450
                Award ID: NIH R21AI145450
                Award ID: NIH R21AI145450
                Award ID: NIH R21AI145450
                Award ID: NIH R21AI145450
                Award ID: NIH R21AI145450
                Award ID: NIH R21AI145450
                Award ID: NIH R21AI145450
                Award ID: NIH R21AI145450
                Award ID: NIH R21AI145450
                Award ID: NIH R21AI145450
                Award ID: NIH R21AI145450
                Award ID: NIH R21AI145450
                Award ID: NIH R21AI145450
                Award ID: NIH R21AI145450
                Award ID: NIH R21AI145450
                Award ID: NIH R21AI145450
                Award Recipient :
                Funded by: University of Washington/Fred Hutch Center for AIDS Research
                Award ID: NIH P30AI027757
                Award ID: NIH P30AI027757
                Award ID: NIH P30AI027757
                Award ID: NIH P30AI027757
                Award ID: NIH P30AI027757
                Award ID: NIH P30AI027757
                Award ID: NIH P30AI027757
                Award ID: NIH P30AI027757
                Award ID: NIH P30AI027757
                Award ID: NIH P30AI027757
                Award ID: NIH P30AI027757
                Award ID: NIH P30AI027757
                Award ID: NIH P30AI027757
                Award ID: NIH P30AI027757
                Award ID: NIH P30AI027757
                Award ID: NIH P30AI027757
                Award ID: NIH P30AI027757
                Award ID: NIH P30AI027757
                Award ID: NIH P30AI027757
                Award Recipient :
                Categories
                Research
                Custom metadata
                © The Author(s) 2022

                Health & Social care
                viral suppression,viral load testing,point-of-care,children,pregnant/postpartum women,kenya

                Comments

                Comment on this article